A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
To identify the maximum tolerable dose and assess qualitative/quantitative toxicities in
patients with advanced renal cell cancer treated with combination of 5-azacitidine and
bevacizumab.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Kansas University of Kansas Medical Center